China Resources Shuanghe announced that the company has received the “Drug Supplement Application Approval Notice” for sulugen glucosamine injections issued by the State Drug Administration. According to the notice, the company's application for additional specifications for sodium sulugenosaccharide injections complies with the relevant requirements for drug registration, approves the additional specifications, and issues a new drug approval number, which is valid for 12 months. As of the announcement date, the company's cumulative R&D investment for the drug was RMB 2.555,500, according to the total amount of 5 ml:500 mg of the active substance of the sodium sulugene glucosamine active entity and the active entity of mono-hydroxyglucosamine.

China Resources Shuanghe announced that the company has received the “Drug Supplement Application Approval Notice” for sulugen glucosamine injections issued by the State Drug Administration. According to the notice, the company's application for additional specifications for sodium sulugenosaccharide injections complies with the relevant requirements for drug registration, approves the additional specifications, and issues a new drug approval number, which is valid for 12 months. As of the announcement date, the company's cumulative R&D investment for the drug was RMB 2.555,500, according to the total amount of 5 ml:500 mg of the active substance of the sodium sulugene glucosamine active entity and the active entity of mono-hydroxyglucosamine.